Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: Use of high-range Etest strips

Journal of Clinical Microbiology

Volumn 43, Issue 9, 2005, Pages 4480-4485

  Morosini, María I ^a   García Castillo, María ^a   Loza, Elena ^a   Pérez Vázquez, María ^b   Baquero, Fernando ^a   Cantón, Rafael ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

AGAR DILUTION METHOD; ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CYSTIC FIBROSIS; DEVICE; DILUTION; DRUG RESPONSE; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERFORMANCE; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STANDARD;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PREDICTIVE VALUE OF TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REAGENT STRIPS; TOBRAMYCIN;

PSEUDOMONAS AERUGINOSA;

EID: 24744432307     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.9.4480-4485.2005     Document Type: Article

References (35)

1. Barclay, M. L., and E. J. Begg. 2001. Aminoglycoside adaptive resistance: importance for effective dosage regimens. Drugs 61:713-721.
2. Barclay, M. L., E. J. Begg, S. T. Chambers, P. E. Thornley, P. K. Pattemore, and K. Grimwood. 1996. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. J. Antimicrob. Chemother. 37:1155-1164,
3. Biedenbach, D. J., I. H. Schermer, and R. N. Jones. 1997. Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices. Diagn. Microbiol. Infect. Dis. 27:1-5.
4. Burns, J. L., J. M. Van Dalfsen, R. M. Shawar, K. L. Otto, R. L. Garber, J. M. Quan, A. B. Montgomery, G. M. Albers, B. W. Ramsey, and A. L. Smith. 1999. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 179:1190-1196.
5. Burns, J. L., L. Saiman, S. Whittier, D. Larone, J. Krzewinski, Z. Liu, S. A. Marshall, and R. N. Jones. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J. Clin. Microbiol. 38:1818-1822.
6. Canton, R., N. Cobos, J. de Gracia, F. Baquero, J. Honorato, S. Gartner, A. Álvarez, A. Salcedo, A. Oliver, E. García-Quetglas, et al. 2005. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin. Microbiol. Infect. 11:690-703.
7. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. CLSI/NCCLS M100-S15. Clinical and Laboratory Standards Institute, Wayne, Pa.
8. Doring, G., S. P. Conway, H. G. Heijerman, M. E. Hodson, N. Høiby, A. Smyth, and D. J. Touw. 2000. Antimicrobial therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 16:749-767.
9. Doring, G., N. Høiby, et al. 2004. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J. Cystic Fibrosis 3:67-91.
10. Gales, A. C., A. O. Reis, and R. N. Jones. 2001. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J. Clin. Microbiol. 39:183-190.
11. Geller, D. E., W. H. Pitlick, P. A. Nardella, W. G. Tracewell, and B. W. Ramsey. 2002. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122:219-226.
12. Gibson, R. L., J. L. Burns, and B. W. Ramsey. 2003. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168:918-951.
13. Hocquet, D., C. Vogne, F. El Garch, A. Vejux, N. Gotoh, A. Lee, O. Lomovskaya, and P. Plésiat. 2003. MexXY-OprM efflux pump is necessary for adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob. Agents Chemother. 47:1371-1375.
14. Hodson, M. E., and C. G. Gallagher. 2002. New clinical evidence from the European tobramycin trial in cystic fibrosis. J. Cystic Fibrosis 1(Suppl. 2):199-202.
15. Jacques, I., J. Derelle, M. Weber, and M. Vidailhet. 1998. Pulmonary evolution of cystic fibrosis patients colonized by Pseudomonas aeruginosa and/or Burkholderia cepacia. Eur. J. Pediatr. 157:427-431.
16. LiPuma, J. J. 2001. Microbiological and immunologic considerations with aerosolized drug delivery. Chest 120:1185-1235.
17. Lyczak, J. B., C. L. Cannon, and G. B. Pier. 2002. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15:194-222.
18. Maciá, M. D., N. Borrell, J. L. Pérez, and A. Oliver. 2004. Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with Etest and disk diffusion. Antimicrob. Agents Chemother. 48:2665-2672.
19. Mah, T. F. B., B. Pitts, B. Pellock, G. C. Walker, P. S. Stewart, and G. A. O'Toole. 2003. A genetic basis for Pseudomonas aeruginosa biofilm antimicrobial resistance. Nature 426:306-310.
20. Mesa Española de Normalización de la Sensibilidad y Resistencia a los Antimicrobianos. 2005. Recomendaciones del grupo MENSURA para la selection de antimicrobianos en el estudio de la sensibilidad y criterios para la interpretación del antibiograma. MENSURA, Madrid, Spain.
21. National Committee for Clinical Laboratory Standards. 2001. Development of in vitro susceptibility testing criteria and quality control parameters, 2nd ed. Document M23-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
22. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 6th ed. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
23. National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial disk susceptibility tests, 8th ed. Approved standard M2-A8. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. Oliver, A., R. Cantón, P. Campo, F. Baquero, and J. Blázquez. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1254.
25. Oliver, A., B. R. Levin, C. Juan, F. Baquero, and J. Blázquez. 2004. Hypermutation and the preexistence of antimicrobial-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob. Agents Chemother. 48:4226-4233.
26. Poole, K. 2005. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:479-487.
27. Rajan, S., and L. Saiman. 2002. Pulmonary infections in patients with cystic fibrosis. Semin. Respir. Infect. 17:47-56.
28. Ramsey, B. W., M. S. Pepe, J. M. Quan, K. L. Otto, A. B. Montgomery, J. Williams-Warren, K. M. Vasiljev, D. Borowitz, C. M. Bowman, B. C. Marshall, S. Marshall, and A. L. Smith. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis: cystic fibrosis inhaled tobramycin group. N. Engl. J. Med. 340:23-30.
29. Ratjen, F., G. Doling, and W. H. Nikolaizik. 2001. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Lancet 358:983-984.
30. Rosenfeld, M., R. Gibson, S. McNamara, J. Emerson, K. S. McCoyd, R. Shell, D. Borowitz, M. W. Konstan, G. Retsch-Bogart, R. W. Wilmott, J. L. Burns, P. Vicini, A. B. Montgomery, and B. Ramsey. 2001. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J. Pediatr. 139:572-577.
31. Rosenfeld, M., B. W. Ramsey, and R. L. Gibson. 2003. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr. Opin. Pulm. Med. 9:492-497.
32. Schülin, T. 2002. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J. Antimicrob. Chemother. 49:403-406.
33. Smith, A. L., B. W. Ramsey, D. L. Hedges, B. Hack, J. Williams-Warren, A. Weber, E. J. Gore, and G. J. Redding. 1989. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr. Pulmonol. 7:265-271.
34. Singh, P. K., A. L. Schaefer, M. R. Parsek, T. O. Moninger, M. J. Welsh, and E. P. Greeenberg. 2000. Quorum sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407:762-764.
35. Yankaskas, J. R., B. C. Marshall, B. Suflan, R. H. Simon, and D. Rodman. 2004. Cystic fibrosis adult care: consensus conference report. Chest 125(Suppl. 1):1-39.